Preformulation evaluation of AZD1305, an oxabispidine intended for oral and intravenous treatment

References

• Palucki M, Higgins JD, Kwong E, Templeton AC. (2010). Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. J Med Chem, 53:5897–5905.
   PubMed Web of Science ®Google Scholar
• Qin X, Frech P. (2001). Liquid chromatography/mass spectrometry (LC/MS) identification of photooxidative degradates of crystalline and amorphous MK-912. J Pharm Sci, 90:833–844.
   PubMed Web of Science ®Google Scholar
• Shah RB, Bryant A, Collier J, Habib MJ, Khan MA. (2008). Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. Int J Pharm, 360:77–82.
   PubMed Web of Science ®Google Scholar
• Yoshioka S, Stella VJ. (2000). Stability of drugs and dosage forms. New York: Kluwer Academic/Plenum Publishers.
   Google Scholar
• Matsuda Y, Teraoka R, Sugimoto I. (1989). Comparative evaluation of photostability of solid-state nifedipine under ordinary and intensive light irradiation conditions. Int J Pharm, 54:211–221.
   Web of Science ®Google Scholar
• De Villiers MM, van der Watt JG, Lötter AP. (1992). Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide. Int J Pharm 88:275–283.
   Web of Science ®Google Scholar
• Ahmad I, Ansari IA, Ismail T. (2003). Effect of nicotinamide on the photolysis of cyanocobalamin in aqueous solution. J Pharm Biomed Anal, 31:369–374.
   PubMed Web of Science ®Google Scholar
• Glass BD, Novak C, Brown ME. (2004). The thermal and photostability of solid pharmaceuticals. J Therm Anal Cal 77:1013–1036.
   Web of Science ®Google Scholar
• Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. (1992). Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int J Pharm 86:25–33.
   Web of Science ®Google Scholar
• Desai DS, Abdelnasser MA, Rubitski BA, Varia SA. (1994). Photostabilization of uncoated tablets of sorivudine and nifedipine by incorporation of synthetic iron oxides. Int J Pharm 103:69–76.
   Web of Science ®Google Scholar
• Aman W, Thoma K. (2002). The influence of formulation and manufacturing process on the photostability of tablets. Int J Pharm, 243:33–41.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Andersson T, Nilsson L, Schönbacher V, Wang Y. (2007). Pharmaceutical and analytical characterisation of (2R)-(3-amino-2-fluoropropyl)sulphinic acid, a GABAB receptor agonist. Eur J Pharm Biopharm, 65:104–110.
   PubMed Web of Science ®Google Scholar
• Wan H, Holmén AG, Wang Y, Lindberg W, Englund M, Någård MB et al. (2003). High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry. Rapid Commun Mass Spectrom, 17:2639–2648.
   PubMed Web of Science ®Google Scholar
• ACD/Labs 6.00 C. ACD pKa DB. West Toronto, Ontario, Canada: Advanced Chemistry Development Inc.
   Google Scholar
• Stephenson GA, Aburub A, Woods TA. (2011). Physical stability of salts of weak bases in the solid-state. J Pharm Sci, 100:1607–1617.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Obach RS, Shalaeva MY, Gao F. (2002). Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem, 45:2867–2876.
   PubMed Web of Science ®Google Scholar
• Avdeef A. (2001). Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem, 1:277–351.
   PubMedGoogle Scholar
• Hirsch CA, Messenger RJ, Brannon JL. (1978). Fenoprofen: drug form selection and preformulation stability studies. J Pharm Sci, 67:231–236.
   PubMed Web of Science ®Google Scholar
• Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. (2000). Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm, 198:239–247.
   PubMed Web of Science ®Google Scholar
• Stahl PH, Wermuth CG, eds. (2002). Handbook of pharmaceutical salts, properties, selection and use. Weinheim: IUPAC, Wiley-VCH.
   Google Scholar
• Aakeröy CB, Fasulo ME, Desper J. (2007). Cocrystal or salt: does it really matter? Mol Pharm, 4:317–322.
   PubMed Web of Science ®Google Scholar
• Schultheiss N, Newman A. (2009). Pharmaceutical Cocrystals and Their Physicochemical Properties. Cryst Growth Des, 9:2950–2967.
   PubMed Web of Science ®Google Scholar
• Brittain HG. (1999). Polymorphism in pharmaceutical solids. New York: Marcel Dekker.
   Google Scholar
• Byrn SR, Pfeiffer RR, Stowell JG. (1999). Solid state chemistry of drugs, 2nd edn. West Lafayette: SSCI Inc.
   Google Scholar
• Bernstein J. (2002). Polymorphism in molecular crystals. Oxford: Clarendon Press.
   Google Scholar
• Thirunahari S, Aitipamula S, Chow PS, Tan RB. (2010). Conformational polymorphism of tolbutamide: A structural, spectroscopic, and thermodynamic characterization of Burger’s forms I-IV. J Pharm Sci, 99:2975–2990.
   PubMedGoogle Scholar
• Huang LF, Tong WQ. (2004). Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev, 56:321–334.
   PubMed Web of Science ®Google Scholar
• Gardner CR, Walsh CT, Almarsson O. (2004). Drugs as materials: valuing physical form in drug discovery. Nat Rev Drug Discov, 3:926–934.
   PubMed Web of Science ®Google Scholar
• Hilfiker R. (2006). Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH.
   Google Scholar
• Muller M, Meier U, Wieckhusen D, Beck R, Pfeiffer-Henning S, Schneeberger R. (2006). Process development strategy to ascertain reproducible API polymorph manufacture. Cryst Growth Des 6:946–954.
   Web of Science ®Google Scholar
• Kato F, Otsuka M, Matsuda Y. (2006). Kinetic study of the transformation of mefenamic acid polymorphs in various solvents and under high humidity conditions. Int J Pharm, 321:18–26.
   PubMed Web of Science ®Google Scholar
• Kojima T, Onoue S, Katoh F, Teraoka R, Matsuda Y, Kitagawa S et al. (2007). Effect of spectroscopic properties on photostability of tamoxifen citrate polymorphs. Int J Pharm, 336:346–351.
   PubMedGoogle Scholar
• Pan C, Liu F, Motto M. (2011). Identification of pharmaceutical impurities in formulated dosage forms. J Pharm Sci 100:1228–1258.
   PubMed Web of Science ®Google Scholar
• The benefit risk profile was judged unfavourable and the AZD1305 development program was discontinued.
   Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. (2011). Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm, 37:243–251.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Nordmark A, Theilig S, Lindahl A. (2011). A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm, 37:185–192.
   PubMed Web of Science ®Google Scholar
• Martinez M, Amidon G, Clarke L, Jones WW, Mitra A, Riviere J. (2002). Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Adv Drug Deliv Rev, 54:825–850.
   PubMed Web of Science ®Google Scholar
• Sutton SC. (2004). Companion animal physiology and dosage form performance. Adv Drug Deliv Rev, 56:1383–1398.
   PubMed Web of Science ®Google Scholar
• Russell TL, Berardi RR, Barnett JL, Dermentzoglou LC, Jarvenpaa KM, Schmaltz SP et al. (1993). Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm Res, 10:187–196.
   PubMed Web of Science ®Google Scholar
• Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 46:75–87.
   PubMed Web of Science ®Google Scholar